What is the equity of Cellectis this year?
Cellectis has equity of 84.69 M USD this year.
Cellectis Equity 2024
Cellectis Equity
84.69 M USD
Ticker
ALCLS.PA
ISIN
FR0010425595
WKN
A0MKPR
In 2024, Cellectis's equity was 84.69 M USD, a -28.21% increase from the 117.97 M USD equity in the previous year.
Cellectis Aktienanalyse
What does Cellectis do?
Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Cellectis's Equity
Cellectis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cellectis's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Cellectis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Cellectis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Cellectis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Cellectis stock
What was the equity of Cellectis compared to the previous year?
The equity of Cellectis has increased/decreased by -28.21% decreased compared to the previous year.
What impact does a high equity have on investors of Cellectis?
A high equity is advantageous for investors of Cellectis as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Cellectis?
A low equity can be a risk for investors of Cellectis, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Cellectis affect the company?
An increase in equity of Cellectis can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Cellectis affect the company?
A reduction in equity of Cellectis can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Cellectis?
Some factors that can affect the equity of Cellectis include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Cellectis so important for investors?
The equity of Cellectis is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Cellectis take to change the equity?
To change equity, Cellectis can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Cellectis pay?
Over the past 12 months, Cellectis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectis is expected to pay a dividend of 0 USD.
What is the dividend yield of Cellectis?
The current dividend yield of Cellectis is .
When does Cellectis pay dividends?
Cellectis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Cellectis?
Cellectis paid dividends every year for the past 0 years.
What is the dividend of Cellectis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Cellectis located?
Cellectis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cellectis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cellectis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Cellectis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Cellectis in the year 2023?
In the year 2023, Cellectis distributed 0 USD as dividends.
In which currency does Cellectis pay out the dividend?
The dividends of Cellectis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Cellectis stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Cellectis
Our stock analysis for Cellectis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
